BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

310 related articles for article (PubMed ID: 32236507)

  • 21. Adjuvant Imatinib for High-Risk GI Stromal Tumor: Analysis of a Randomized Trial.
    Joensuu H; Eriksson M; Sundby Hall K; Reichardt A; Hartmann JT; Pink D; Ramadori G; Hohenberger P; Al-Batran SE; Schlemmer M; Bauer S; Wardelmann E; Nilsson B; Sihto H; Bono P; Kallio R; Junnila J; Alvegård T; Reichardt P
    J Clin Oncol; 2016 Jan; 34(3):244-50. PubMed ID: 26527782
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Long-term survival outcome with tyrosine kinase inhibitors and surgical intervention in patients with metastatic or recurrent gastrointestinal stromal tumors: A 14-year, single-center experience.
    Kim JH; Ryu MH; Yoo C; Chae H; Na H; Beck M; Kim BS; Yoo MW; Yook JH; Kim BS; Kim KH; Kim CW; Kang YK
    Cancer Med; 2019 Mar; 8(3):1034-1043. PubMed ID: 30693663
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term follow-up of patients with GIST undergoing metastasectomy in the era of imatinib -- analysis of prognostic factors (EORTC-STBSG collaborative study).
    Bauer S; Rutkowski P; Hohenberger P; Miceli R; Fumagalli E; Siedlecki JA; Nguyen BP; Kerst M; Fiore M; Nyckowski P; Hoiczyk M; Cats A; Casali PG; Treckmann J; van Coevorden F; Gronchi A
    Eur J Surg Oncol; 2014 Apr; 40(4):412-9. PubMed ID: 24491288
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumors.
    Cohen MH; Johnson JR; Justice R; Pazdur R
    Oncologist; 2012; 17(7):992-7. PubMed ID: 22643537
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Is there a role of surgery in patients with recurrent or metastatic gastrointestinal stromal tumours responding to imatinib: a prospective randomised trial in China.
    Du CY; Zhou Y; Song C; Wang YP; Jie ZG; He YL; Liang XB; Cao H; Yan ZS; Shi YQ
    Eur J Cancer; 2014 Jul; 50(10):1772-1778. PubMed ID: 24768330
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Analysis of gastric gastrointestinal stromal tumors in Shandong Province: a midterm report of multicenter GISSG1201 study].
    Hou Q; Luo W; Li L; Dai Y; Jiang L; Wang A; Chu X; Li Y; Yang D; Lu C; Yao L; Cui G; Lin H; Chen G; Cui Q; Zhang H; Lun Z; Xia L; Su Y; Han G; Hui X; Wei Z; Sun Z; Guo H; Zhou Y
    Zhonghua Wei Chang Wai Ke Za Zhi; 2017 Sep; 20(9):1025-1030. PubMed ID: 28900994
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy of Long-Term Adjuvant Therapy With Imatinib Mesylate After Extensive Surgical Treatment for Ruptured Gastrointestinal Stromal Tumors of the Small Intestine With Peritoneal Metastases: A Case Report.
    Kimura T; Togawa T; Onishi K; Iida A; Sato Y; Goi T
    J Investig Med High Impact Case Rep; 2020; 8():2324709620970736. PubMed ID: 33228387
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Adjuvant imatinib treatment after R0 resection for patients with high-risk gastrointestinal stromal tumors: a median follow-up of 44 months.
    Jiang WZ; Guan GX; Lu HS; Yang YH; Kang DY; Huang HG
    J Surg Oncol; 2011 Dec; 104(7):760-4. PubMed ID: 21713778
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is 3-years duration of adjuvant imatinib mesylate treatment sufficient for patients with high-risk gastrointestinal stromal tumor? A study based on long-term follow-up.
    Lin JX; Chen QF; Zheng CH; Li P; Xie JW; Wang JB; Lu J; Chen QY; Cao LL; Lin M; Tu RH; Huang CM
    J Cancer Res Clin Oncol; 2017 Apr; 143(4):727-734. PubMed ID: 28083710
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Retrospective analysis of 85 cases of intermediate-risk gastrointestinal stromal tumor.
    Fu Y; Hao H; Guo L; Yang G; Zhang X
    Oncotarget; 2017 Feb; 8(6):10136-10144. PubMed ID: 28052037
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Gastric gastrointestinal stromal tumors: therapeutic strategies and long-term prognosis.
    Shou C; Chen Z; Li Z; Yang W; Zhang Q; Bai H; Yu J
    Scand J Gastroenterol; 2024; 59(2):239-245. PubMed ID: 37865826
    [TBL] [Abstract][Full Text] [Related]  

  • 32. [Significance of surgical treatment for recurrent and metastatic gastrointestinal stromal tumors].
    Zhang XH; He YL
    Zhonghua Wei Chang Wai Ke Za Zhi; 2020 Sep; 23(9):840-844. PubMed ID: 32927506
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Postoperative imatinib in patients with intermediate risk gastrointestinal stromal tumor.
    Wu X; Li J; Xu W; Gao J; Li Y; Shen L
    Future Oncol; 2018 Jul; 14(17):1721-1729. PubMed ID: 29969914
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Safety of Imatinib Mesylate in a Multicenter Expanded Access Program in Adult Patients with Gastrointestinal Stromal Tumors in the Adjuvant Setting.
    Reichardt P; Schlemmer M; Delgado Perez JR; Papai Z; Prausova J; Melichar B; Fumagalli E; Barone C; Bauer S; Pustowka A; Crippa S; Castellana R; Quiering C; Le Cesne A
    Oncol Res Treat; 2019; 42(12):629-635. PubMed ID: 31550719
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Rectal Gastrointestinal Stromal Tumor (GIST) in the Era of Imatinib: Organ Preservation and Improved Oncologic Outcome.
    Cavnar MJ; Wang L; Balachandran VP; Antonescu CR; Tap WD; Keohan M; Singer S; Temple L; Nash GM; Weiser MR; Guillem JG; Aguilar JG; DeMatteo RP; Paty PB
    Ann Surg Oncol; 2017 Dec; 24(13):3972-3980. PubMed ID: 29058144
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Adjuvant systemic therapy for small bowel gastrointestinal stromal tumor (GIST): Is there a survival benefit after R0 resection?
    Patel DJ; Lutfi W; Eguia E; Sweigert P; Knab L; Abood G; Baker MS
    Surgery; 2020 Oct; 168(4):695-700. PubMed ID: 32713755
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Clinical characteristics and prognosis analysis of 119 cases with giant gastrointestinal stromal tumor].
    Zhang P; Zeng X; Gao J; Liu W; Shuai X; Liu K; Liu X; Cai M; Cai K; Wang G; Tao K
    Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1290-1295. PubMed ID: 27928802
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Preoperative imatinib facilitates complete resection of locally advanced primary GIST by a less invasive procedure.
    Yang W; Yu J; Gao Y; Shen Q; Zhang Q; Liu X; Zhao Z; Shi X; Zhu K; Ma Y
    Med Oncol; 2014 Sep; 31(9):133. PubMed ID: 25056206
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Imatinib-resistant gastrointestinal stromal tumors in the era of second- and third-line tyrosine kinase inhibitors: Does surgical resection have a role?
    Sutton TL; Walker BS; Billingsley KG; Sheppard BC; Corless CL; Heinrich MC; Mayo SC
    Surgery; 2021 Nov; 170(5):1481-1486. PubMed ID: 34090672
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Adherence to adjuvant with therapy imatinib in patients with gastrointestinal stromal tumor: a national multi-center cross-sectional study].
    Zhang P; Zhang J; Zhang B; Yang WC; Hu JB; Sun XF; Zhai G; Qian HR; Li Y; Xu H; Feng F; Wu XY; Liu HL; Liu HJ; Qiu HB; Wu XJ; Zhou YB; Shen KT; Kou YW; Fu Y; Jie ZG; Zou XM; Cao H; Gao ZD; Tao KX
    Zhonghua Wei Chang Wai Ke Za Zhi; 2021 Sep; 24(9):775-782. PubMed ID: 34530558
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 16.